Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease
| العنوان: | Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease |
|---|---|
| المؤلفون: | Eleonora Scorletti, Albandri Alshathry, Mark Wright, Jaswinder K. Sethi, Caroline E. Childs, Stefania Del Fabbro, Charles Peebles, Debbie E. Smith, Amal Almehmadi, Angela Darekar, Helen Moyses, Geraldine F. Clough, Paul R. Afolabi, Josh Bilson, Richard Aspinall, Janisha Patel, Philip C. Calder, Giovanni Targher, Laure B. Bindels, Elizabeth A. Miles, Joanna Dowman, Christopher D. Byrne, Nathalie M. Delzenne, Andrew Fowell, Valerio Nobili, David J. Breen |
| المساهمون: | UCL - SSS/LDRI - Louvain Drug Research Institute |
| المصدر: | Gastroenterology, Vol. 158, no. 6, p. 1597-1610.e7 (2020) Gastroenterology |
| بيانات النشر: | Elsevier BV, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Liver Cirrhosis, Male, 0301 basic medicine, Magnetic Resonance Spectroscopy, Synbiotics, Biopsy, medicine.medical_treatment, Oligosaccharides, Type 2 diabetes, Gastroenterology, Feces, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Weight loss, Cardiovascular Disease, Nonalcoholic fatty liver disease, Middle Aged, Cardiovascular disease, Lipids, Type 2 Diabetes, Liver, Elasticity Imaging Techniques, Female, 030211 gastroenterology & hepatology, medicine.symptom, Adult, medicine.medical_specialty, Placebo, Proof of Concept Study, Article, INSYTE Study, Nutrition, 03 medical and health sciences, Bifidobacterium animalis, Double-Blind Method, Internal medicine, Diabetes mellitus, medicine, Humans, Hepatology, business.industry, Prebiotic, medicine.disease, United Kingdom, Gastrointestinal Microbiome, 030104 developmental biology, INSYTE study, Dysbiosis, Transient elastography, business, Biomarkers |
| الوصف: | BACKGROUND & AIMS: Dysbiosis of the intestinal microbiota has been associated with nonalcoholic fatty liver disease (NAFLD). We investigated whether administration of a synbiotic combination of probiotic and prebiotic agents affected liver fat content, biomarkers of liver fibrosis, and the composition of the fecal microbiome in patients with NAFLD.METHODS: We performed a double-blind phase 2 trial of 104 patients with NAFLD in the United Kingdom. Participants (mean age, 50.8 ± 12.6 years; 65% men; 37% with diabetes) were randomly assigned to groups given the synbiotic agents (fructo-oligosaccharides, 4 g twice per day, plus Bifidobacterium animalis subspecies lactis BB-12; n = 55) or placebo (n = 49) for 10-14 months. Liver fat content was measured at the start and end of the study by magnetic resonance spectroscopy, and liver fibrosis was determined from a validated biomarker scoring system and vibration-controlled transient elastography. Fecal samples were collected at the start and end of the study, the fecal microbiome were analyzed by 16S ribosomal DNA sequencing.RESULTS: Mean baseline and end-of-study magnetic resonance spectroscopy liver fat percentage values were 32.3% ± 24.8% and 28.5% ± 20.1% in the synbiotic group and 31.3% ± 22% and 25.2% ± 17.2% in the placebo group. In the unadjusted intention-to-treat analysis, we found no significant difference in liver fat reduction between groups (β = 2.8; 95% confidence interval, -2.2 to 7.8; P = .30). In a fully adjusted regression model (adjusted for baseline measurement of the outcome plus age, sex, weight difference, and baseline weight), only weight loss was associated with a significant decrease in liver fat (β = 2; 95% confidence interval, 1.5-2.6; P = .03). Fecal samples from patients who received the synbiotic had higher proportions of Bifidobacterium and Faecalibacterium species, and reductions in Oscillibacter and Alistipes species, compared with baseline; these changes were not observed in the placebo group. Changes in the composition of fecal microbiota were not associated with liver fat or markers of fibrosis.CONCLUSIONS: In a randomized trial of patients with NAFLD, 1 year of administration of a synbiotic combination (probiotic and prebiotic) altered the fecal microbiome but did not reduce liver fat content or markers of liver fibrosis. (ClinicalTrials.gov, Number: NCT01680640). |
| وصف الملف: | text; image |
| تدمد: | 0016-5085 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3857e54022068c72805f39fe3e794afdTest https://doi.org/10.1053/j.gastro.2020.01.031Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3857e54022068c72805f39fe3e794afd |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00165085 |
|---|